Market Place
Sourcing Support
Orexo Initiates Study of OX640 in Allergic Rhinitis
25 Oct 2024 //
PR NEWSWIRE
Orexo Interim Report Q3 2024
24 Oct 2024 //
PR NEWSWIRE
Orexo´s Nomination Committee for the Annual General Meeting 2025
04 Oct 2024 //
PR NEWSWIRE
Orexo to Participate in Pareto Securities’ Annual Healthcare Conference
03 Sep 2024 //
PR NEWSWIRE
Orexo Q2 2024 Interim Report
17 Jul 2024 //
PR NEWSWIRE
Orexo AB´s sustainability work ranked among top 5% by EcoVadis
10 Jul 2024 //
PR NEWSWIRE
Orexo: invitation to presentation of the Q2 2024 Interim Report
08 Jul 2024 //
PR NEWSWIRE
Orexo Prospectus, Nasdaq Stockholm Social Bonds Listing
10 May 2024 //
PR NEWSWIRE
Orexo Q1 2024 Interim Report
08 May 2024 //
PR NEWSWIRE
Report from Orexo AB`s annual general meeting, 26 April 2024
26 Apr 2024 //
PR NEWSWIRE
Orexo extends patent protection for its nasal epinephrine powder product OX640
22 Apr 2024 //
INDINPHARMAPOST
Orexo Extends US Patent Protection for Nasal Epinephrine OX640
17 Apr 2024 //
PR NEWSWIRE
Orexo Announces that The Condition for Early Redemption of Its Existing Bonds
02 Apr 2024 //
PR NEWSWIRE
Orexo publishes the Annual and Sustainability Report for 2023
28 Mar 2024 //
PR NEWSWIRE
Notice of Annual General Meeting of Orexo
15 Mar 2024 //
PR NEWSWIRE
Orexo issues senior secured callable floating rate social bonds of SEK 500 m
13 Mar 2024 //
PR NEWSWIRE
Orexo contemplates issuance of secured callable floating rate social bonds
08 Mar 2024 //
PR NEWSWIRE
Orexo strengthens its sustainability work by establishing a financing framework
08 Mar 2024 //
PR NEWSWIRE
Orexo and Sobi agree to advance feasibility study with AmorphOX
12 Feb 2024 //
PR NEWSWIRE
Orexo Interim Report Q4 2023, incl. Full Year Report
08 Feb 2024 //
PR NEWSWIRE
Orexo`s OX640 development results to be presented at the 2024 AAAAI
06 Feb 2024 //
PR NEWSWIRE
Orexo announces FDA acceptance of New Drug Application filing for OX124
28 Nov 2023 //
PR NEWSWIRE
Orexo Q3 2023 Interim Report
02 Nov 2023 //
PR NEWSWIRE
Orexo announces changes in the company´s Board of Directors
27 Oct 2023 //
PR NEWSWIRE
Report from Orexo´s extraordinary general meeting
26 Oct 2023 //
PR NEWSWIRE
Orexo´s Nomination Committee for the Annual General Meeting 2024
26 Oct 2023 //
PR NEWSWIRE
Orexo announces data from the MODIA® study evaluating illicit opioids
11 Oct 2023 //
PR NEWSWIRE
Notice of Extraordinary General Meeting in Orexo AB (publ)
03 Oct 2023 //
PR NEWSWIRE
Orexo submits New Drug Application to FDA for OX124
18 Sep 2023 //
PR NEWSWIRE
Orexo to participate in Pareto Securities´ 14th Annual Healthcare Conference
05 Sep 2023 //
PR NEWSWIRE
Orexo secures patent protection in the US for OX640, a nasal epinephrine powder
29 Aug 2023 //
PR NEWSWIRE
Orexo`s patent win for ZUBSOLV® appealed
24 Jul 2023 //
PR NEWSWIRE
Orexo Q2 2023 Interim Report
18 Jul 2023 //
PR NEWSWIRE
Orexo wins patent litigation for ZUBSOLV® in the US
01 Jul 2023 //
PR NEWSWIRE
Orexo Interim Report Q1 2023
27 Apr 2023 //
PR NEWSWIRE
Report from Orexo AB`s annual general meeting
18 Apr 2023 //
PR NEWSWIRE
Orexo shares timeline for high-dose rescue medication for opioid overdose, OX124
03 Apr 2023 //
PR NEWSWIRE
Orexo publishes the Annual and Sustainability Report for 2022
28 Mar 2023 //
PR NEWSWIRE
Notice of Annual General Meeting of Orexo
15 Mar 2023 //
PR NEWSWIRE
Orexo postpones publication of the Annual Report
15 Mar 2023 //
PR NEWSWIRE
Orexo seeks approval of nasal high-dose opioid rescue medicine
08 Feb 2023 //
FIERCE PHARMA
Orexo submits New Drug Application to FDA for OX124
03 Feb 2023 //
PR NEWSWIRE
Orexo Interim Report Q4 2022, incl. Full Year Report
26 Jan 2023 //
PR NEWSWIRE
Orexo initiates feasibility studies of amorphOX with twovaccine companies
09 Jan 2023 //
PR NEWSWIRE
Orexo´s Nomination Committee for the Annual General Meeting 2023
17 Oct 2022 //
PRNEWSWIRE
Orexo announces positive data from phase 1 clinical study for OX640
11 Oct 2022 //
PRNEWSWIRE
Orexo’s adrenaline product OX640 receives European patent
02 Sep 2022 //
PHARMABIZ
First patent issued in Europe for Orexo`s adrenaline product OX640
01 Sep 2022 //
PRNEWSWIRE
Orexo Interim Report Q2 2022
14 Jul 2022 //
PRNEWSWIRE
Orexo`s digital therapy deprexis reimbursed under the US Veterans Affairs
13 Jul 2022 //
PRNEWSWIRE
Orexo`s nasal adrenaline rescue medication OX640 enters clinical development
05 Jul 2022 //
PRNEWSWIRE
Orexo Interim Report Q1 2022
28 Apr 2022 //
PRNEWSWIRE
Gesynta Pharma receives orphan drug designation by FDA for systemic sclerosis
27 Apr 2022 //
PHARMAFILE
Orexo publishes 2021 Annual Report
31 Mar 2022 //
PRNEWSWIRE
Orexo appoints Fredrik Järrsten as new CFO
11 Mar 2022 //
PRNEWSWIRE
Sober Grid collaborates with Walgreens and Orexo
09 Mar 2022 //
PRNEWSWIRE
Orexo`s lead product ZUBSOLV® added to NY State Medicaid MAT Preferred Drug List
24 Feb 2022 //
PRNEWSWIRE
Orexo Q4 2021, incl. Full Year Report
27 Jan 2022 //
PRNEWSWIRE
Orexo develops nasal adrenaline medication based on novel amorphOX platform
04 Dec 2021 //
PHARMABIZ
Orexo announces positive results from pivotal trial of OX124
16 Nov 2021 //
PRNEWSWIRE
